Fabio Torelli
About Fabio Torelli
Fabio Torelli is an Associate Director of Cell Therapy at Kite Pharma, where he has worked since 2018. He has extensive experience in oncology and cell therapy, having held positions at Gilead Sciences and Pfizer, and holds multiple degrees in medicine and drug development.
Current Role at Kite Pharma
Fabio Torelli currently serves as the Associate Director of Cell Therapy at Kite Pharma, a position he has held since 2018. Based in Milano, Italia, he has been instrumental in advancing the company's cell therapy initiatives. His experience in this role encompasses overseeing various aspects of cell therapy projects and collaborating with cross-functional teams to enhance therapeutic outcomes.
Previous Experience at Kite Pharma
Before his current role, Fabio Torelli worked as a Senior Medical Project Manager in Cell Therapy at Kite Pharma for a duration of six months in 2018. During this period in Milano, Italia, he contributed to the management and execution of medical projects related to cell therapy, leveraging his expertise in the field.
Professional Background at Gilead Sciences
Fabio Torelli was employed at Gilead Sciences from 2014 to 2018, where he held the position of Medical Scientist in Oncology for three years. He later transitioned to a Senior Medical Scientist role within the same organization for ten months. His work at Gilead Sciences involved research and development in oncology, contributing to the advancement of therapeutic options.
Educational Qualifications
Fabio Torelli has a robust educational background. He studied at Sapienza Università di Roma, where he specialized in Hematology, achieving a Specialization in Hematology from 2005 to 2009. Additionally, he earned a Master's degree in Preclinical and Clinical Drug Development from Università Cattolica del Sacro Cuore in 2014. He also holds a degree in Medicine and Surgery from Sapienza Università di Roma, completed from 1999 to 2005.
Experience at Pfizer
Fabio Torelli worked at Pfizer in various capacities. He served as a Medical Science Liaison (MSR) for Hemophilia from 2012 to 2014 and as an MSR Advisor for Rare Diseases for three months in 2014. His roles involved engaging with healthcare professionals and providing scientific support related to Pfizer's therapeutic products.